This review will provide an overview of the use rucaparib and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC) with the goal to assist the clinician's decision-making process when considering these agents for an individual patient.
Data Sources
Searches were conducted in PubMed, relevant meeting abstracts, clinicaltrials.gov, and United States Food and Drug Administration (FDA) documents to identify literature published through July 1, 2021, related to use of rucaparib and olaparib for treatment of prostate cancer.
Data Summary
In May 2020, the FDA approved rucaparib and olaparib for treatment of mCRPC that is homologous recombination repair (HRR)-deficient. Both agents are approved for previously-treated patients, but there are notable differences in strength of evidence, outcomes studied, required HRR alteration, and required prior therapies. In patients who qualify for therapy, additional factors that may help guide choice of PARP inhibitor include baseline organ function, drug interaction potential, toxicity profiles, and financial factors.
Conclusions
Rucaparib and olaparib have the potential to improve outcomes for patients with HRR-deficient mCRPC. Differences in strength of evidence and patient- and drug-specific characteristics will assist the clinician when choosing between agents.
LathamASrinivasanPKemelY, et al.Microsatellite instability is associated with the presence of lynch syndrome pan-cancer. J Clin Oncol2019; 37: 286–295.
4.
AbidaWChengMLArmeniaJ, et al.Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol2019; 5: 471–478.
MoasserMMAiWZ. Neoplasia. In: HammerGDMcPheeSJ (eds) Pathophysiology of disease: an Introduction to clinical medicine. 8e. New York, NY: McGraw-Hill Education, 2019.
9.
CastroEGohCOlmosD, et al.Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol2013; 31: 1748–1757.
10.
WeiYWuJGuW, et al.Prognostic value of germline DNA repair gene mutations in De Novo metastatic and castration-sensitive prostate cancer. Oncologist2020; 25: e1042–e1e50.
11.
PageECBancroftEKBrookMN, et al.Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers. Eur Urol2019; 76: 831–842.
12.
Olaparib. In: Lexi-drugs online [database on the internet]. Hudson (OH): Lexicomp, Inc.; 2021[updated 5 Jun 2021; cited 28 Jun 2021]. Available from: http://online.lexi.com. Subscription required to view.
13.
Rucaparib. Lexi-drugs online [database on the internet]. Hudson (OH): Lexicomp, Inc., 2021 [updated 30 Apr 2021; cited 28 Jun 2021]. Available from:http://online.lexi.com. Subscription required to view.
14.
WellsteinAGiacconeGAtkinsMB, et al.Pathway-Targeted therapies: monoclonal antibodies, protein kinase inhibitors, and Various small molecules. In: BruntonLLHilal-DandanRKnollmannBC (eds) Goodman & Gilman's: the pharmacological basis of therapeutics. 13e. New York, NY: McGraw-Hill Education, 2017.
15.
National Center for Biotechnology Information. PARP1 poly(ADP-ribose) polymerase 1 [Homo sapiens (human)], https://www.ncbi.nlm.nih.gov/gene/142 (2021, accessed 30 June 2021).
16.
PrasadRHortonJKWilsonSH. Requirements for PARP-1 covalent crosslinking to DNA (PARP-1 DPC). DNA Repair (Amst)2020; 90: 102850.
17.
MurthyPMuggiaF. PARP Inhibitors: clinical development, emerging differences, and the current therapeutic issues. Cancer Drug Resistance2019; 2: 665–679.
Rubraca (rucaparib) tablets [package insert on the internet]. Boulder (CO): Clovis Oncology, Inc.2020[revised May 2020; cited 2021 May 3]. Available from: https://clovisoncology.com/pdfs/RubracaUSPI.pdf.
20.
ShapiroGIKristeleitRSBurrisHA, et al.Pharmacokinetic study of rucaparib in patients with advanced solid tumors. Clin Pharmacol Drug Dev2019; 8: 107–118.
21.
PlummerRSwaislandHLeunenK, et al.Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours. Cancer Chemother Pharmacol2015; 76: 723–729.
22.
LiaoMWatkinsSNashE, et al.Evaluation of absorption, distribution, metabolism, and excretion of [(14)C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors. Invest New Drugs2020; 38: 765–775.
23.
AngJEClarkson-JonesJASwaislandH, et al.405 A mass balance study to investigate the metabolism, excretion and pharmacokinetics of [14C]-olaparib (AZD2281) in patients with advanced solid tumours refractory to standard treatments. European Journal of Cancer Supplements2010; 8: 128–129.
24.
GrechkoNSkarbovaVTomaszewska-KiecanaM, et al.Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment. Cancer Chemother Pharmacol2021; 88:259–270.
25.
XiaoJJNowakDRamlauR, et al.Evaluation of drug-drug interactions of rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp substrates in patients with an advanced solid tumor. Clin Transl Sci.2019; 12: 58–65.
ConnorTHMacKenzieBADeBordDG, et al. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings, 2016. https://www.cdc.gov/niosh/docs/2016-161/(2016, accessed 30 June 2021).
28.
NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings: Proposed Additions to the NIOSH Hazardous Drug List 2018, https://www.federalregister.gov/d/2018-02957 (2018, accessed 30 June 2021).
FongPCBossDSYapTA, et al.Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med2009; 361: 123–134.
32.
KaufmanBShapira-FrommerRSchmutzlerRK, et al.Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol2015; 33: 244–250.
33.
MateoJCarreiraSSandhuS, et al.DNA-Repair Defects and olaparib in metastatic prostate cancer. N Engl J Med2015; 373: 1697–1708.
34.
MateoJPortaNBianchiniD, et al.Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol2020; 21: 162–174.
35.
de BonoJMateoJFizaziK, et al.Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med2020; 382: 2091–2102.
36.
AbidaWPatnaikACampbellD, et al.Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol2020; 38: 3763–3772.
37.
AbidaWCampbellDPatnaikA, et al.Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study. Clin Cancer Res2020; 26: 2487–2496.
38.
HussainMMateoJFizaziK, et al.Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med2020; 383: 2345–2357.
ColemanRLOzaAMLorussoD, et al.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2017; 390: 1949–1961.
42.
OzaAMTinkerAVOakninA, et al.Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from study 10 and ARIEL2. Gynecol Oncol2017; 147: 267–275.
TewWPLacchettiCEllisA, et al.PARP Inhibitors in the management of ovarian cancer: ASCO guideline. J Clin Oncol2020; 38: 3468–3493.
45.
Kwon DH, Booth CM, Prasad V. Untangling the PROfound trial for advanced prostate cancer: is there really a role for olaparib?. Eur Urol 2021; 79: 710–712.
46.
U.S. National Library of Medicine. Clinicaltrials.gov(2021, accessed 7 July 2021)..
